[脏病学中的抗炎治疗进展:我们可以从心脏病学中学习吗?]
Deutsche medizinische Wochenschrift (1946)
|February 21, 2025
概括
系统性低级炎症驱动慢性病 (CKD) 的进展和并发症. 抗炎疗法,包括新获批准的菌素,在治疗慢性病和降低心血管疾病风险方面表现有前途.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 心脏病学 心脏病学
背景情况:
- 无菌炎症是病病理学的一个关键特征,包括淋巴结核炎和移植后的移植.
- 系统性低级炎症越来越多地被认为对慢性病 (CKD) 进展及其相关并发症的作用.
研究的目的:
- 审查CKD患者中低度炎症的原因和后果.
- 探索抗炎策略减缓CKD进展的潜力.
- 在患有或没有CKD的患者中概述动脉样硬化的抗炎疗法.
主要方法:
- 文献综述侧重于CKD中低级炎症的病因和后果.
- 对慢性脏病的抗炎方法最近取得的进展进行分析.
- 讨论FDA批准的胆固醇治疗动脉样硬化及其对CKD患者的影响.
主要成果:
- 低度炎症显著影响CKD的进展和并发症.
- 抗炎疗法为治疗CKD提供了新的机会.
- 科尔奇辛对动脉样硬化的批准为相关的CKD患者群体提供了治疗途径.
结论:
- 抗炎疗法可以改善CKD的进展,并抑制急性至慢性病的转变.
- 这些方法可以降低患心血管疾病等长期并发症的风险.
- 针对炎症是脏病学和心脏病学中一个有前途的策略.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
371
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
Hormonal Regulation
32.8K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
32.8K
Heart Failure Drugs: Diuretics
334
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
334
Antihypertensive Drugs: Direct Renin Inhibitors
469
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
469
Inflammatory Bowel Disease IV: Pharmacological Management
89
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
89
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
455
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
455


